tirzepatide news november 2025 New data show most patients now stay on Wegovy, Zepbound after a year New drug tirzepatide delivers significant Company of the Year 2025:

Diabetes 61(2):292300

Retatrutide is a triple agonist that activates GLP-1, GIP, and glucagon receptors simultaneously, whereas semaglutide targets only GLP-1 and tirzepatide targets GLP-1 and GIP

Nature 642 , 10161023 (2025)

Avoid repeated temperature cycling, and never freeze a reconstituted vial, which can precipitate the peptides out of solution

But, there are additional benefits you might not know

If severe abdominal pain develops particularly persistent epigastric pain no further doses should be taken and urgent medical or trial team review should be sought (see the section below on when to seek medical advice)